ArticleCureus2025
Pilot Feasibility and Preliminary Cost Implications of a Day-Case Head and Neck Surgery Pathway Incorporating ARTISS Fibrin Sealant.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThe objective of this study was to evaluate the feasibility, safety, and preliminary cost implications of implementing a standardized day-case pathway for common head and neck procedures that incorporates ARTISS fibrin sealant (human).
designThis was a single-center, retrospective pilot service evaluation of consecutive cases.
settingThe study was conducted at a UK National Health Service (NHS) district general hospital (day surgery unit without inpatient beds).
participantsParticipants included consecutive adults between October 2024 and February 2025 who underwent selected head and neck procedures judged suitable for day-case management under a predefined pathway.
interventionA protocolized bundle including meticulous hemostasis, ARTISS applied at closure to promote adhesion and reduce dead space, drain avoidance where feasible (surgeon discretion permitted), structured recovery and explicit discharge criteria, and written or telephone safety-netting.
main outcome measuresThe primary outcome was same-day discharge, and the secondary outcomes included unplanned overnight admission, return to the operating room, 30-day readmission, hematoma or seroma, drain use, and other adverse events. A provider-perspective cost-consequence analysis compared day-case delivery with procedure-specific inpatient length of stay (LOS) estimates from the literature, and one-way sensitivity analyses were performed varying LOS, bed-day costs, and ARTISS price.
resultsTwenty-nine patients underwent day-case head and neck surgery; 25/29 (86.2%; 95% CI 69.4-94.5) were discharged the same day. No returns to the operating room or 30-day readmissions for hemorrhage or seroma were observed (95% upper bound 10.3%). Drains were used in 1/29 (3.4%; 95% CI 0.6-17.2). Base-case modeling indicated bed-day cost savings versus inpatient care.
conclusionsA standardized day-case pathway that incorporates ARTISS was feasible in this retrospective pilot, with a preliminary favorable safety profile and cost consequences in an NHS setting. As a single-center, non-comparative study, findings are preliminary and cannot isolate the independent effect of ARTISS. Future studies should include multicenter comparative evaluation (ARTISS versus no ARTISS within the same pathway) and formal economic analysis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.